Corbus Pharmaceuticals Holdings, Inc. Increase (Decrease) in Prepaid Expenses, Other
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Increase (Decrease) in Prepaid Expenses, Other of $1.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpensesOther · last filed 2026-08-06
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in prepaid expenses, other for the quarter ending 2026-06-30 was -$150.00K, a 109.04% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in prepaid expenses, other for the quarter ending 2026-03-31 was $1.95M, a 195.45% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in prepaid expenses, other for the quarter ending 2025-12-31 was -$297.00K, a 112.60% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in prepaid expenses, other for the quarter ending 2025-09-30 was -$2.66M, a 606.87% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in prepaid expenses, other for fiscal 2025 was -$634.00K, a 151.59% decline from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in prepaid expenses, other for fiscal 2024 was $1.23M, a 16.39% decline from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in prepaid expenses, other for fiscal 2023 was $1.47M.
| Period end | Increase (Decrease) in Prepaid Expenses, Other 3 month | Increase (Decrease) in Prepaid Expenses, Other 3 month as first filed | Increase (Decrease) in Prepaid Expenses, Other 6 month | Increase (Decrease) in Prepaid Expenses, Other 9 month | Increase (Decrease) in Prepaid Expenses, Other 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$150.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.80M 10-Q · filed 2026-08-06 | $1.50M derived: sum of 3 quarters · filed 2026-08-06 | -$1.16M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $1.95M 10-Q · filed 2026-05-12 | $1.65M derived: sum of 2 quarters · filed 2026-05-12 | -$1.01M derived: sum of 3 quarters · filed 2026-05-12 | $654.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$2.95M derived: sum of 2 quarters · filed 2026-03-09 | -$1.29M derived: sum of 3 quarters · filed 2026-08-06 | -$634.00K 10-K · filed 2026-03-09 | |
| 2025-09-30 | -$2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$996.00K derived: sum of 2 quarters · filed 2026-08-06 | -$337.00K 10-Q · filed 2025-11-12 | $2.02M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.32M 10-Q · filed 2026-08-06 | $4.68M derived: sum of 3 quarters · filed 2026-08-06 | $5.20M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $659.00K 10-Q · filed 2026-05-12 | $3.02M derived: sum of 2 quarters · filed 2026-05-12 | $3.54M derived: sum of 3 quarters · filed 2026-05-12 | $3.12M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.88M derived: sum of 2 quarters · filed 2026-03-09 | $2.46M derived: sum of 3 quarters · filed 2026-03-09 | $1.23M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $524.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $100.00K derived: sum of 2 quarters · filed 2025-11-12 | -$1.13M 10-Q · filed 2025-11-12 | -$1.04M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$424.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$1.65M 10-Q · filed 2025-08-05 | -$1.56M derived: sum of 3 quarters · filed 2025-08-05 | -$882.00K derived: sum of 4 quarters · filed 2025-08-05 | |
| 2024-03-31 | -$1.23M 10-Q · filed 2025-05-06 | -$1.23M 10-Q · filed 2024-05-07 | -$1.14M derived: sum of 2 quarters · filed 2025-05-06 | -$458.00K derived: sum of 3 quarters · filed 2025-05-06 | -$320.22K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $771.00K derived: sum of 2 quarters · filed 2025-03-11 | $908.78K derived: sum of 3 quarters · filed 2025-03-11 | $1.47M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $678.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $815.78K derived: sum of 2 quarters · filed 2024-11-07 | $1.38M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $137.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $699.00K 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $561.22K 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |